Contact
Privacy Policy

Copyright © DEEPNOID Inc. All rights reserved.

Back to list
Medical AI

DEEPNOID Signs MOU with KMI Korea Medical Institute for AI Monitoring Research on Health Screening Result Assessment

May 15, 2025
DEEPNOID Signs MOU with KMI Korea Medical Institute for AI Monitoring Research on Health Screening Result Assessment

Photo 1. (Left) Kwang Bae Lee, Chairman of KMI Korea Medical Institute; (Right) Woo Sik Choi, CEO of DEEPNOID

- Introducing an LLM-based AI system to support clinicians with fast and accurate health screening data processing
- Expanding the scope of medical AI services, with personalized health screening services expected for everyday health management

DEEPNOID, one of Korea’s first-generation medical AI companies (CEO Woo Sik Choi), announced on May 15, 2025, that it signed a memorandum of understanding (MOU) with KMI Korea Medical Institute (KMI; Chairman Kwang Bae Lee) on May 9 for AI monitoring research on health screening result assessment. With this agreement, DEEPNOID plans to fully expand its business into the health screening market.
Under the agreement, the two organizations will pursue research on a large language model (LLM)-based screening system, improve the accuracy of health screening result report reviews using generative AI technology, and conduct joint research and commercialization in medical imaging technology.
The partnership aims to deliver personalized health screening services by combining KMI’s extensive health screening data with DEEPNOID’s generative AI technology. DEEPNOID plans to introduce an LLM-based AI system to regularly automate the review of health screening data and improve its efficiency. Using the refined data, KMI will support clinicians in making fast and accurate decisions. By delivering screening results in a timely manner, the partnership is also expected to improve examinee satisfaction and the efficiency of health screening services.
The system can also be readily extended to other medical information platforms, laying the groundwork for greater precision in medical data overall.
The agreement is expected to expand the use of medical AI beyond lesion interpretation to everyday health management and health screening data processing, broadening the reach of medical AI services.
“Through this agreement, we expect to increase the value of the health screening data KMI has accumulated over more than 40 years and to strengthen the effectiveness of our health screening services using generative AI technology,” said Kwang Bae Lee, Chairman of KMI Korea Medical Institute.
“We expect KMI’s accumulated medical expertise and data to create a powerful synergy with our AI technology,” said Woo Sik Choi, CEO of DEEPNOID. “We hope this agreement marks a turning point in extending the use of medical AI into everyday health management.”
Founded in 1985, KMI Korea Medical Institute is a health screening institution that operates health screening centers in eight locations nationwide: three in Seoul (Gwanghwamun, Yeouido, and Gangnam) and five in other regions (Suwon, Daegu, Busan, Gwangju, and Jeju). In addition to its work on early disease detection, prevention, and public health promotion, KMI carries out a range of social contribution programs.
DEEPNOID, one of Korea’s first-generation medical AI companies, researches and develops medical image analysis solutions that support the diagnosis and treatment guidance of diseases such as cerebral aneurysms and lung diseases. Its key medical AI solutions include DEEP:NEURO, which was provisionally listed as a non-reimbursable service under Korea’s National Health Insurance in 2024; M4CXR, a generative AI-based draft report generation solution for chest X-ray (CXR); and DEEP:CHEST, a real-time detection and diagnosis-assistance solution for multiple lung diseases.

###